

Postmenopausal osteoporosis - Pipeline Insight, 2021

<https://marketpublishers.com/r/PFC6EE3DA37EN.html>

Date: May 2021

Pages: 60

Price: US\$ 2,000.00 (Single User License)

ID: PFC6EE3DA37EN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Postmenopausal osteoporosis - Pipeline Insight, 2021," report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Postmenopausal osteoporosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Postmenopausal osteoporosis Understanding

Postmenopausal osteoporosis: Overview

Osteoporosis is a metabolic bone disorder that is characterized by low bone mass and micro-architectural deterioration of bone tissue. Fractures of the proximal femur, the vertebrae and the distal radius are the most frequent osteoporotic fractures, although most fractures in the elderly are probably at least partly related to bone fragility. The incidence of fractures varies greatly by country, but on average up to 50% of women >50 years of age are at risk of fractures. Fractures severely affect the quality of life of an individual and are becoming a major public health problem owing to the ageing population. Postmenopausal osteoporosis, resulting from oestrogen deficiency, is the most common type of osteoporosis. Oestrogen deficiency results in an increase in bone turnover owing to effects on all types of bone cells. The imbalance in bone formation

and resorption has effects on trabecular bone (loss of connectivity) and cortical bone (cortical thinning and porosity).

'Postmenopausal osteoporosis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Postmenopausal osteoporosis pipeline landscape is provided which includes the disease overview and Postmenopausal osteoporosis treatment guidelines. The assessment part of the report embraces, in depth Postmenopausal osteoporosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Postmenopausal osteoporosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Postmenopausal osteoporosis R&D. The therapies under development are focused on novel approaches to treat/improve Postmenopausal osteoporosis.

Postmenopausal osteoporosis Emerging Drugs Chapters

This segment of the Postmenopausal osteoporosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Postmenopausal osteoporosis Emerging Drugs

TVB-009: Teva Pharmaceutical

TVB-009 is a Denosumab biosimilar being developed by Teva Pharmaceutical for the treatment of patients with Postmenopausal osteoporosis. TVB-009 is a RANK ligand inhibitor and is currently in phase 3 of clinical trials.

Blosozumab: Eli Lilly and Company

Blosozumab is a humanised IgG4 monoclonal antibody, being developed by Eli Lilly and Company, for the treatment of postmenopausal osteoporosis. It is a SOST protein inhibitor and is currently in phase 2 of clinical trials.

Further product details are provided in the report

Postmenopausal osteoporosis: Therapeutic Assessment

This segment of the report provides insights about the different Postmenopausal osteoporosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Postmenopausal osteoporosis

There are approx. 20+ key companies which are developing the therapies for Postmenopausal osteoporosis. The companies which have their Postmenopausal osteoporosis drug candidates in the most advanced stage, i.e. phase III include, Teva Pharmaceutical.

Phases

DelveInsight's report covers around 20+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Postmenopausal osteoporosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravitreal

Subretinal

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Postmenopausal osteoporosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Postmenopausal osteoporosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Postmenopausal osteoporosis drugs.

Postmenopausal osteoporosis Report Insights

- Postmenopausal osteoporosis Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Postmenopausal osteoporosis Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Postmenopausal osteoporosis drugs?

How many Postmenopausal osteoporosis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Postmenopausal osteoporosis?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Postmenopausal osteoporosis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Postmenopausal osteoporosis and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Teva Pharmaceutical

Eli Lilly and Company

Shanghai Biomabs Pharmaceutical

HEXAL

Samsung Bioepis

Qilu Pharmaceutical

Shenzhen Salubris Pharmaceuticals

Jiangsu HengRui Medicine Co., Ltd.

Celltrion

Mabwell (Shanghai) Bioscience Co., Ltd.

Huons Co., Ltd.

Entera Bio Ltd.

PhytoHealth

Reliance Life Sciences

Enteris BioPharma

Luye Pharma

Sandoz International GmbH

Shanghai Henlius Biotech

Haoma Medica

Outlook Therapeutics

Key Products

TVB-009

Blosozumab

CMAB-807

GP-2411

SB 16

QL1206

rhPTH(1-34)

SHR-1222

CT-P41

MW031

HUG186-B

EBP05

PHN-031

R-TPR-045

Calcitonin oral

LY06006

HLX14

NaQuinate

ONS-4010

Contents

Introduction

Executive Summary

Postmenopausal osteoporosis: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Postmenopausal osteoporosis – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Postmenopausal osteoporosis companies' collaborations, Licensing, Acquisition -Deal Value Trends

Postmenopausal osteoporosis Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

TVB-009: Teva Pharmaceutical

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Mid Stage Products (Phase II)

Comparative Analysis

Blosozumab: Eli Lilly and Company

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Inactive Products

Comparative Analysis

Postmenopausal osteoporosis Key Companies

Postmenopausal osteoporosis Key Products

Postmenopausal osteoporosis- Unmet Needs

Postmenopausal osteoporosis- Market Drivers and Barriers

Postmenopausal osteoporosis- Future Perspectives and Conclusion

Postmenopausal osteoporosis Analyst Views

Postmenopausal osteoporosis Key Companies

Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Postmenopausal osteoporosis
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Postmenopausal osteoporosis
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Postmenopausal osteoporosis - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/PFC6EE3DA37EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PFC6EE3DA37EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970